Gilead Sciences saw a notable increase in its stock price following a significant partnership announcement.
Gilead Sciences Inc (NASDAQ:GILD) experienced a robust gain of 3.80% in its stock price yesterday, closing at CA$153.54. This uptick followed the announcement of a collaboration with Vir Biotechnology aimed at developing innovative therapies for solid tumors.
Advertisement
Gilead Sciences Inc
GILD.US
GILD.US
Gilead Sciences Inc
WealthAwesomeMarket cap
$190.38B
Div. yield
2.18%
Div. / share
$3.22
52W high
$160.51
52W low
$111.27
1W change
+6.98%
Beta
0.33
Analyst Price Targets
Based on 28 analysts covering GILD · as of Oct 16, 2026
Wall Street analysts forecast GILD stock price to rise 403.2% over the next 12 months.
Consensus
Buy4.32 / 5.00
Avg. Target
C$159.58
+403.2% Upside
Previously C$159.62 on Oct 14, 2026
Current Price
C$31.71
Last close
Analyst Breakdown (28 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GILD's historical volatility
30-Day Vol
23.9%
Annualized
90-Day Vol
28.1%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$188.14
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$167.02 | C$153.78 – C$181.41 |
| 60 trading days | C$177.27 | C$157.72 – C$199.24 |
| 90 trading days | C$188.14 | C$163.05 – C$217.09 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The partnership with Vir Biotechnology could enhance Gilead's oncology portfolio and diversify its revenue streams, which is crucial for the company's long-term growth strategy.
3.80% Gain
Gilead's stock rose significantly, reflecting investor optimism about its new strategic direction in oncology.
Bull case
The collaboration with Vir Biotechnology brings advanced technology that could lead to effective new therapies in oncology. This partnership may position Gilead as a leader in the solid tumor treatment market.
Bear case
Despite the positive news, Gilead faces challenges in execution and competition within the oncology space. These factors could affect the actual revenue growth from this partnership.
Advertisement
Strategic Partnership with Vir Biotechnology
The recent collaboration between Gilead and Vir Biotechnology focuses on developing dual-masked T cell engagers for solid tumors. This partnership grants Gilead exclusive rights to advance these promising cancer therapies, leveraging Vir's expertise in immunology and antibody engineering. The potential for innovative treatments could significantly bolster Gilead's oncology portfolio, which is essential for its growth strategy.
Market Reaction and Future Outlook
Investors reacted positively to the news, as evidenced by the 3.80% increase in Gilead's stock price. This gain reflects optimism about the company's ability to diversify its pipeline and generate sustainable revenue growth. However, analysts caution that Gilead must navigate competitive pressures and execution challenges in the oncology market to fully capitalize on this partnership.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
